The currentavailability of synthetic ligands should help to further dissect PPAR-δ-mediated responses in the brain as well as in other functions not addressed inthis issue, including gut and skin homesotasis.Although challenges for the development of PPAR-δagonists remains, they clearly holdgreat therapeutic promise, ashighlighted by recent clinical findings indicating that MBX-8025, one of themost advanced PPAR-δ agonists currently in phaseII clinical trial for dyslipidemia,displays hypolipidemic features not observed with the currentlyavailable dyslipidemiatherapies [6, 7]. Here, PPARD is linked to metabolic syndrome.